New study reveals Caduet two-in-one pill dramatically improves patient adherence
-Patient adherence essential in reducing risk of cardiovascular disease-
KIRKLAND, QC, July 7 /CNW/ - Despite the proven benefits of blood pressure and cholesterol medications for the prevention of cardiovascular events(1) and guidelines supporting an integrated approach to the reduction of cardiovascular risk,(2) few patients receive adequate treatment for the prevention of cardiovascular disease. This is due in part to poor patient adherence to cardiovascular medications.
According to a new study, Caduet Adherence Related PharmacoEconomic Value Model (CARPE-V), published in this month's Vascular Health and Risk Management, patients taking CADUET(R) were more likely to be adherent and persistent with therapy compared to patients taking calcium channel blockers (CCB) and statins as two separate pills. CADUET combines the efficacy of the blood pressure lowering medication, NORVASC(R), with the cholesterol and cardiovascular risk reduction of LIPITOR(R).
"The findings from CARPE-V reinforce the importance of adherence when it comes to managing a person's risk factors for cardiovascular disease," says Dr. George Honos, Associate Professor of Medicine, McGill University, Montreal. "CADUET allows me to simplify my patients' treatment regime by providing them with the proven benefits of two leading treatments in the convenience of one single pill. By reducing pill burden and synchronizing high blood pressure and high cholesterol treatment, we are significantly helping to reduce our patient's chance of suffering a heart attack or stroke."
Managing Multiple Risk Factors Early
Cardiovascular disease, including heart disease and stroke, is the leading cause of death in Canada.(3) Unfortunately, Canadians run a high risk of developing cardiovascular disease. Research shows that an alarming 80 per cent of Canadians have at least one modifiable risk factor for cardiovascular disease, such as high cholesterol, hypertension, obesity and a sedentary lifestyle.(4)
A number of studies, including the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), have shown that managing multiple risk factors may help to significantly reduce a patient's likelihood of suffering a cardiovascular event. The ASCOT study found that using a NORVASC-based blood pressure lowering treatment regimen in combination with LIPITOR, a statin, significantly reduced cardiovascular events, such as heart attacks, in patients with high blood pressure and additional cardiovascular risk factors.
CADUET is a prescription drug that combines two medicines, NORVASC (amlodipine besylate) and LIPITOR (atorvastatin calcium), which have been extensively studied in clinical trials.
NORVASC is a prescription drug indicated in the treatment of mild to moderate essential hypertension. NORVASC is also indicated for the management of chronic stable angina (effort-associated angina) in patients who remain symptomatic despite adequate dose of beta blockers and/or organic nitrates or who cannot tolerate those agents.
LIPITOR is a drug prescribed to lower cholesterol and other fats in the blood (such as triglycerides) when response to diet and other lifestyle measures have been inadequate, in both adults and children (aged 10 to 17 years). LIPITOR is also indicated to prevent cardiovascular disease such as heart attacks. High levels of cholesterol and other fats can cause heart disease by clogging the blood vessels that feed blood and oxygen to the heart.
The two agents forming CADUET are still available separately.
About Pfizer Canada Inc.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world's leading pharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer's ongoing research and development activities focus on a wide range of therapeutic areas following our guiding aspiration: working together for a healthier world. For more information, visit www.pfizer.ca.
(1) ALLHAT Officers and Coordinator for the ALLHAT Collaborative Research
Group, 2002; Sever, et al 2003; Staessen et al 2003; Baigent et al 2005.
(2) Expert Panel on Detection Evaluation and Treatment of High
Cholesterol in Adults, 2001).
(4) Tipping the Scales of Progress. Heart Disease and Stroke in Canada,
2006. Heart and Stroke Foundation of Canada.
For further information: Laura Espinoza, Edelman, (416) 979-1120, ext. 245, firstname.lastname@example.org; Christian Marcoux, Pfizer Canada Inc., (514) 426-6985, email@example.com/
Posted: July 2008